Table 2 Time to deterioration of functional status in FACT-P total scale and subscales

From: Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study

 

25th percentile (95% CI)a, months

HR (95% CI)

P value

Rezvilutamide plus ADT (n = 326)

Bicalutamide plus ADT (n = 328)

FACT-P total scale

12.8 (7.4–20.3)

6.0 (4.6–9.2)

0.66 (0.50–0.86)

0.002

Physical well-being

18.4 (8.3–36.8)

7.4 (5.6–11.1)

0.65 (0.49–0.86)

0.003

Social/family well-being

4.6 (3.6–6.5)

4.6 (3.7–5.6)

0.89 (0.70–1.13)

0.332

Emotional well-being

29.0 (14.9–NR)

12.4 (8.3–18.4)

0.68 (0.50–0.92)

0.013

Functional well-being

4.7 (3.7–6.5)

4.2 (2.8–5.5)

0.75 (0.59–0.95)

0.015

FACT-G general scale

12.8 (7.4–23.9)

8.4 (5.6–12.6)

0.69 (0.52–0.91)

0.008

Prostate cancer subscale

9.2 (6.5–13.8)

5.5 (3.8–7.3)

0.74 (0.57–0.96)

0.022

Trial outcome index

14.8 (7.4–27.6)

8.2 (5.7–11.1)

0.65 (0.49–0.86)

0.002

FACT-P pain scale

5.6 (3.7–7.4)

4.6 (3.7–6.2)

0.85 (0.67–1.08)

0.184

  1. aThe 25th percentiles were reported here because the majority of the median values had not been reached
Back to article page